Oocyte donation outcome after oncological treatment in cancer survivors

Monday, December 29, 2014
The reproductive outcomes of oocyte donation from women cured of cancer are similar to those from women without previous cancer, regardless of cancer type.

Read More

Defining the specific reproductive effects of cancer therapies The burden is upon us

Tuesday, June 24, 2014
Reflections on "Impact of lymphoma treatments on spermatogenesis and sperm DNA: a multicenter prospective study from the CECOS network" by Bujan et al.

Read More

Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid A multicenter prospective study from the CECOS network

Monday, June 2, 2014
Lymphoma treatments had highly damaging effects on spermatogenesis and sperm chromatin quality. Mean pretreatment sperm concentrations were recovered at 12months after doxorubicin, bleomycin, vinblastine, darcarbacine (ABVD) or ABVD + radiotherapy, but at 24 months after doxorubicin, cyclophosphamide, vincristine, prednisone(CHOP) ormechlorethamine, oncovin, procarbazine, prednisone (MOPP) therapies.

Read More

Effects of chemotherapy and radiotherapy on spermatogenesis in humans

Thursday, October 31, 2013
Short- and long-term effects of radiotherapy, cytotoxic cancer chemotherapy, and biologic targeted therapies on human spermatogenesis are summarized and interpreted based on kinetics of spermatogenesis and recovery from stem cells.

Read More

Impact of chemotherapy and radiotherapy for testicular cancer on spermatogenesis and sperm DNA a multicenter prospective study from CECOS Network

Friday, August 30, 2013
Adjuvant treatments for testicular germ cell tumors have drastic effects on spermatogenesis and sperm chromatin quality; pretreatment values were recovered >12 months after >2 BEP cycles or after radiotherapy.

Read More

Antimüllerian hormone the assessment of the ovarian reserve and the reproductive outcome of the young patient with cancer

Tuesday, April 30, 2013
We discuss the basis for the growing use of AMH in assessment of the ovarian reserve across the lifespan, and its emerging role in assessment before and after cancer treatment.

Read More

Association between the location of transposed ovary and ovarian function in patients with uterine cervical cancer treated with (postoperative or primary) pelvic radiotherapy

Thursday, May 31, 2012
Location of the transposed ovary higher than 1.5 cm above the iliac crest is recommended to avoid ovarian failure after lateral ovarian transposition after primary or adjuvant pelvic radiotherapy.

Read More

Translate »